rasagiline

CLINICAL USE

Treatment of Parkinson’s disease

DOSE IN NORMAL RENAL FUNCTION

1 mg daily

PHARMACOKINETICS

Molecular weight :267.3 (as mesilate)

%Protein binding :60–70

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :243 litres

half-life – normal/ESRD (hrs) :0.6–2/unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Likely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Analgesics: avoid concomitant use with dextromethorphan; avoid concomitant use with pethidine (risk of serious adverse reactions) – allow at least 14 days before starting pethidine

Antidepressants: avoid concomitant use with other MAOIs (can lead to hypertensive crisis) – allow at least 14 days before starting a MAOI; avoid concomitant use with fluoxetine and fluvoxamine; allow 5 weeks between stopping fluoxetine and starting rasagiline; allow 14 days between stopping rasagiline and starting fluoxetine or fluvoxamine; increased CNS toxicity with SSRIs and tricyclics

Sympathomimetics: concomitant use is not recommended

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Rasagiline is an irreversible selective inhibitor of monoamine oxidase type B.

Tags: post-by-auto-php